Media stories about Akari Therapeutics PLC (NASDAQ:AKTX) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akari Therapeutics PLC earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.8955427816138 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Akari Therapeutcis (AKTX) Prices 3.48M ADS Offering at $5/Sh (streetinsider.com)
- Akari Therapeutics : Announces Pricing of Public Offering of American Depositary Shares (4-traders.com)
- Akari Therapeutics : Summary ToggleAkari Therapeutics Announces Pricing of Public Offering of American Depositary Shares (4-traders.com)
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.70% (investing.com)
A number of equities research analysts have recently commented on AKTX shares. ValuEngine upgraded shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. Zacks Investment Research upgraded shares of Akari Therapeutics PLC from a “hold” rating to a “strong-buy” rating and set a $4.00 target price for the company in a report on Tuesday, August 29th. William Blair upgraded shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Canaccord Genuity restated a “buy” rating and issued a $15.00 target price (down from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th. Finally, Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics PLC in a report on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $8.00.
Shares of Akari Therapeutics PLC (NASDAQ AKTX) traded down 4.00% on Thursday, reaching $4.32. 415,956 shares of the company’s stock were exchanged. Akari Therapeutics PLC has a 12 month low of $3.18 and a 12 month high of $22.20. The company’s market capitalization is $50.87 million. The firm’s 50 day moving average price is $5.78 and its 200-day moving average price is $7.16.
COPYRIGHT VIOLATION WARNING: “Akari Therapeutics PLC (AKTX) Receives News Sentiment Score of 0.12” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/10/19/akari-therapeutics-plc-aktx-receives-news-sentiment-score-of-0-12.html.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
What are top analysts saying about Akari Therapeutics PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akari Therapeutics PLC and related companies.